Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander M.M. Eggermont, Ulrich Keilholz, Stefan Suciu et al.|The Lancet|2008Cited by 642
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upOlivier Michielin, Ulrich Keilholz, Alexander C. J. van Akkooi et al.|Annals of Oncology|2019Cited by 621
Systematic Review of Medical Treatment in Melanoma: Current Status and Future ProspectsClaus Garbe, John M. Kirkwood, Thomas Eigentler et al.|The Oncologist|2011Cited by 579
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV MelanomaAxel Hauschild, Ulrich Keilholz, Sanjiv S. Agarwala et al.|Journal of Clinical Oncology|2009Cited by 545
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H. Machiels, Ezra E.W. Cohen, Luciano de Souza Viana et al.|The Lancet Oncology|2015Cited by 394